Real-world risk assessment, outcomes and adoption of novel drugs in CLL patients: insights from US databases
Real-world risk assessment, outcomes and adoptio
Promising novel approaches in various B-cell malignancies
Promising novel approaches in various B-cell mal
Phase II data on novel BTK inhibitors for patients with Waldenström’s macroglobulinemia
Phase II data on novel BTK inhibitors for patien
Marginal zone lymphoma: PI3Kδ inhibition and beyond
Marginal zone lymphoma: PI3Kδ inhibition and bey
Mantle cell lymphoma: refining clinical outcomes beyond the current boundaries
Mantle cell lymphoma: refining clinical outcomes
Management of patients with relapsed/refractory CLL: what is new?
Management of patients with relapsed/refractory
Determining first-line CLL/SLL treatment strategies with optimized efficacy and safety
Determining first-line CLL/SLL treatment strateg
Preface
Preface – ASH 2021 Amitkumar Mehta, MD, Di
